Pandion’s lead candidate PT101 has completed a phase 1a clinical trial backing its safety and tolerability, and is due to start a phase 1a/2b study in ulcerative colitis and a phase 2 trial in ...
as the Synthekine deal follows its earlier $1.9 billion takeover of Pandion Therapeutics, which is developing a pipeline of immune system modulators led by IL-2-based drug PT101. Merck has been on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback